Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2714794 | 0.98 | EPHX2 (0.41) | EPHX2ACACBMCHR1SCN5ASCN9A | |
| SCHEMBL11914066 | 0.88 | EPHX2 (0.43) | EPHX2ACACBMCHR1SCN5ASCN9A | |
| SCHEMBL10253315 | 0.84 | L3MBTL1 (0.49) | EPHX2SCN9AKCNH2PDE2A | |
| SCHEMBL10253316 | 0.84 | L3MBTL1 (0.49) | EPHX2SCN9AKCNH2PDE2A | |
| SCHEMBL14480094 | 0.84 | L3MBTL1 (0.49) | EPHX2SCN9AKCNH2PDE2A | |
| SCHEMBL2691179 | 0.84 | L3MBTL1 (0.49) | EPHX2SCN9AKCNH2PDE2A | |
| SCHEMBL16233079 | 0.84 | SCN9A (0.39) | EPHX2SCN5ASCN9AKCNH2PDE2A | |
| Hydrochloric Acid SCHEMBL2714923 | 0.83 | L3MBTL1 (0.48) | EPHX2SCN9AKCNH2PDE2A | |
| Hydrochloric Acid SCHEMBL2713983 | 0.83 | SCN9A (0.38) | EPHX2SCN5ASCN9AKCNH2PDE2A | |
| SCHEMBL2690752 | 0.83 | APP (0.39) | ACACBPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | EPHX2 2460/4885ACACB 1601/4885MCHR1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.